Navigation Links
Novel 'prodrug' alleviates symptoms in Huntington's and Alzheimer's mice
Date:6/2/2011

A study in a special early online publication of Cell, a Cell Press publication, reveals a promising new slow-release compound that protects mice against the neurodegenerative effects of both Huntington's and Alzheimer's disease. The 'prodrug' known only as JM6 works through a pathway involved in the breakdown of the amino acid tryptophan.

Surprisingly, JM6 delivers those benefits even though it doesn't cross the blood-brain barrier and therefore cannot act directly on the brain.

"Most would have assumed that the drug would have to enter the brain to have an effect," said Paul Muchowski of the University of California, San Francisco. He says the new study may therefore pave the way to new strategies for the treatment of brain diseases more broadly.

The kynurenine pathway is a major route of tryptophan breakdown. Scientists had suspected the pathway to play a role in neurodegeneration since the late 1970s, Muchowski said. Metabolites of the pathway can lead to excessive stimulation of neurons, causing damage and even death of the cells.

Muchowski's team started with a compound earlier designed to target an enzyme called kynurenine 3-monooxygenase or KMO.When KMO is inhibited, it shunts the kynurenine pathway in a direction that increases production of a neuroprotective compound known as kynurenic acid (KYNA). KYNA levels are known to decline in Huntington's and Alzheimer's brains.

But the researchers found that the starting compound (Ro 61-8048) was unstable and degraded quickly. Fortunately for Muchowski, his recently retired father Joseph Muchowski is a synthetic chemist with experience in drug development. He enlisted him in generating a slow-release prodrug version of the KMO inhibitor, which they call JM6.

They first treated mice with Huntington's disease with JM6. Chronic delivery of JM6 inhibited KMO in the animals' blood, increasing kynurenic acid levels and reducing extracellular levels of t
'/>"/>

Contact: Elisabeth Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... A research team led by U of T Mississauga scientists ... pair of cancer proteins, a finding that could ultimately lead ... effects. Working with scientists at the University of Central ... the Department of Chemical and Physical Sciences has created several ...
... has shown that the oldest complex life forms -- ... ago likely fed by osmosis. The researchers ... rangeomorphs and the air mattress-shaped erniettomorphs. These macroscopic organisms, ... outer membrane, much like modern microscopic bacteria, according to ...
... Researchers at the University of Oklahoma Health Sciences Center ... gene and high blood pressure. The results, which appear this ... on how we age and how we might live longer. ... factor for stroke, heart attack, heart failure, arterial aneurysm and ...
Cached Biology News:Disrupting a destructive duo: U of T Mississauga researchers inhibit cancer proteins 2Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 2Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 3Anti-aging gene linked to high blood pressure 2
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... 2015 GenomeDx Biosciences today announced ... successfully classified various subtypes of bladder cancer ... biomarkers, including one type associated with resistance ... signature has potential as a tool to ... patients with muscle-invasive bladder cancers (MIBC). The ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
(Date:6/1/2015)... IL (PRWEB) June 01, 2015 ... developing and manufacturing of chiral stationary phases (CSPs) ... options for its current and presenting solutions for ... to its portfolio. This valuable addition to its ... and effective advantage that can tackle projects for ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... N.J., July 18, 2011 Insmed Incorporated ... Andrea ("Andi") Holtzman Drucker, J.D. has been appointed to ... Counsel and Corporate Secretary, effective as of July 18, ... Whitten, President and Chief Executive Officer of Insmed, will ...
... Today the Alzheimer,s Association® in conjunction with ... Global Perspective" panel discussion during the Alzheimer,s Association ... leaders in the Alzheimer,s field and revealed new ... findings explored the impact of Alzheimer,s disease on ...
... SAN DIEGO, July 15, 2011 Biocept, Inc. announced ... Senior Vice President, Finance and Chief Financial Officer.  As ... the company,s accounting, finance, treasury, investor relations, risk management ... years of leadership experience in helping to build life ...
Cached Biology Technology:Andrea Drucker Joins Insmed as General Counsel 2Andrea Drucker Joins Insmed as General Counsel 3Women at the Center of the Global Alzheimer's Epidemic 2Women at the Center of the Global Alzheimer's Epidemic 3Women at the Center of the Global Alzheimer's Epidemic 4Biocept, Inc. Announces New CFO 2Biocept, Inc. Announces New CFO 3
... XS uniquely combines a single-channel sample processing ... 8-channel bulk reagent dispenser all in one ... using disposable pipette tips, the Precision XS ... dispenser is available for transferring larger volumes. ...
... ATP-Gamma-S binds to ATP-binding proteins. To ... FL fluorophore was linked through the ... its potential use for binding studies ... an important new substrate for Fhit ...
... of discovery races ever faster, you need a ... track. So our constant focus is on providing ... Thats why our Biomek 3000 Laboratory Automation Workstation ... as it is flexible. By integrating all aspects ...
... standard microarray image analysis software because of ... tools, visualizations, automation capabilities, performance and ease ... every GenePix scanner, and it also imports ... types of arrays. A wide range of ...
Biology Products: